Literature DB >> 28881872

Hypertension and cardiac arrhythmias: a consensus document from the European Heart Rhythm Association (EHRA) and ESC Council on Hypertension, endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS) and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE).

Gregory Y H Lip1,2, Antonio Coca3, Thomas Kahan4,5, Giuseppe Boriani6, Antonis S Manolis7, Michael Hecht Olsen8, Ali Oto9, Tatjana S Potpara10, Jan Steffel11, Francisco Marín12, Márcio Jansen de Oliveira Figueiredo13, Giovanni de Simone14, Wendy S Tzou15, Chern-En Chiang16, Bryan Williams17, Gheorghe-Andrei Dan18, Bulent Gorenek19, Laurent Fauchier20, Irina Savelieva21, Robert Hatala22, Isabelle van Gelder23, Jana Brguljan-Hitij24, Serap Erdine25, Dragan Lovic26, Young-Hoon Kim27, Jorge Salinas-Arce28, Michael Field29.   

Abstract

Hypertension is a common cardiovascular risk factor leading to heart failure (HF), coronary artery disease, stroke, peripheral artery disease and chronic renal insufficiency. Hypertensive heart disease can manifest as many cardiac arrhythmias, most commonly being atrial fibrillation (AF). Both supraventricular and ventricular arrhythmias may occur in hypertensive patients, especially in those with left ventricular hypertrophy (LVH) or HF. Also, some of the antihypertensive drugs commonly used to reduce blood pressure, such as thiazide diuretics, may result in electrolyte abnormalities (e.g. hypokalaemia, hypomagnesemia), further contributing to arrhythmias, whereas effective control of blood pressure may prevent the development of the arrhythmias such as AF. In recognizing this close relationship between hypertension and arrhythmias, the European Heart Rhythm Association (EHRA) and the European Society of Cardiology (ESC) Council on Hypertension convened a Task Force, with representation from the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE), with the remit to comprehensively review the available evidence to publish a joint consensus document on hypertension and cardiac arrhythmias, and to provide up-to-date consensus recommendations for use in clinical practice. The ultimate judgment regarding care of a particular patient must be made by the healthcare provider and the patient in light of all of the circumstances presented by that patient. Published on behalf of the European Society of Cardiology. All rights reserved.
© The Author 2017. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  Arrhythmias; Atrial fibrillation; EHRA consensus document; Hypertension; Left ventricular hypertrophy

Mesh:

Substances:

Year:  2017        PMID: 28881872     DOI: 10.1093/europace/eux091

Source DB:  PubMed          Journal:  Europace        ISSN: 1099-5129            Impact factor:   5.214


  24 in total

1.  Risk factor paradox: No prognostic impact of arterial hypertension and smoking in patients with ventricular tachyarrhythmias.

Authors:  Kathrin Weidner; Michael Behnes; Jonas Rusnak; Gabriel Taton; Tobias Schupp; Linda Reiser; Armin Bollow; Thomas Reichelt; Dominik Ellguth; Niko Engelke; Philip Kuche; Jorge Hoppner; Ibrahim El-Battrawy; Siegfried Lang; Christoph A Nienaber; Kambis Mashayekhi; Dennis Ferdinand; Christel Weiß; Martin Borggrefe; Ibrahim Akin
Journal:  Cardiol J       Date:  2018-12-19       Impact factor: 2.737

Review 2.  Pathophysiology of Hypertensive Heart Disease: Beyond Left Ventricular Hypertrophy.

Authors:  Chike C Nwabuo; Ramachandran S Vasan
Journal:  Curr Hypertens Rep       Date:  2020-02-03       Impact factor: 5.369

3.  Fragmented QRS as a Marker of Myocardial Fibrosis in Hypertension: a Systematic Review.

Authors:  Mehmet Eyuboglu
Journal:  Curr Hypertens Rep       Date:  2019-08-26       Impact factor: 5.369

Review 4.  Animal Models to Study Cardiac Arrhythmias.

Authors:  Daniel J Blackwell; Jeffrey Schmeckpeper; Bjorn C Knollmann
Journal:  Circ Res       Date:  2022-06-09       Impact factor: 23.213

Review 5.  Antihypertensive therapy and sudden cardiac death, should we expect the unexpected?

Authors:  Elias Sanidas; Konstantinos Malliaras; Dimitrios Papadopoulos; Maria Velliou; Konstantinos Tsakalis; Kanella Zerva; John Barbetseas
Journal:  J Hum Hypertens       Date:  2020-01-14       Impact factor: 3.012

Review 6.  Renal denervation: dark past, bright future?

Authors:  Marshall Heradien; Felix Mahfoud; Doug Hettrick; Paul Brink
Journal:  Cardiovasc J Afr       Date:  2019 Sep/Oct       Impact factor: 1.167

Review 7.  Invited review: hypertension and atrial fibrillation: epidemiology, pathophysiology, and implications for management.

Authors:  Jakub Gumprecht; Magdalena Domek; Gregory Y H Lip; Alena Shantsila
Journal:  J Hum Hypertens       Date:  2019-11-05       Impact factor: 3.012

Review 8.  Rate control strategies for atrial fibrillation.

Authors:  Muath Alobaida; Abdullah Alrumayh
Journal:  Ann Med       Date:  2021-12       Impact factor: 4.709

9.  The Impact of Risk Factors and Comorbidities on The Incidence of Atrial Fibrillation.

Authors:  Nabil Naser; Mirza Dilic; Azra Durak; Mehmed Kulic; Esad Pepic; Elnur Smajic; Zumreta Kusljugic
Journal:  Mater Sociomed       Date:  2017-12

Review 10.  Cardiac arrhythmias in arterial hypertension.

Authors:  Dimitrios Varvarousis; Manolis Kallistratos; Leonidas Poulimenos; Andreas Triantafyllis; Pavlos Tsinivizov; Andreas Giannakopoulos; Konstantinos Kyfnidis; Athanasios Manolis
Journal:  J Clin Hypertens (Greenwich)       Date:  2020-08-09       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.